08:33 AM EST, 12/09/2024 (MT Newswires) -- IDEAYA Biosciences ( IDYA ) said Monday it nominated IDE892 as a development candidate, which it said is a potential methylthioadenosine-cooperative PMRT5 inhibitor.

The oncology company said IDE892 has demonstrated "exceptionally selective" antiproliferative activity in MTAP-deleted tumor cell models.

IDEAYA said ongoing studies of IDE892 are intended to support an investigational new drug filing to the U.S. Food and Drug Administration in mid-2025.